PT-141 Prescription: How to Get One

What “a PT-141 prescription” actually means

PT-141 is the popular name for bremelanotide, a melanocortin-receptor agonist that acts on the brain’s arousal pathways rather than on blood flow. In the US there are two legitimate prescription versions of it, and which one you can get depends largely on who you are.

The first is Vyleesi, an FDA-approved finished drug. It was approved in 2019 and is now marketed by Cosette Pharmaceuticals as an as-needed, prefilled single-dose autoinjector for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Its approved labeling is narrow: it is explicitly not indicated for postmenopausal women, not for men, and not to enhance sexual performance.

The second is compounded bremelanotide, made to order by a licensed compounding pharmacy. This is what most men, postmenopausal women, and anyone using PT-141 outside the HSDD indication actually receive. It is not FDA-approved and is not the same product as Vyleesi.

This page is about the prescribing process itself — who can write the script, how the evaluation works, and what a legitimate path looks like. If you want a side-by-side comparison of the two routes, their costs, and where each is dispensed, that’s covered on how to get PT-141 in the US. Here, the focus is the part both routes share: a real prescription starts with a real evaluation.

Note: No version of PT-141 is sold legally over the counter. Vials labeled “for research use only” are not a patient prescription pathway, and buying them to self-inject sits outside the regulated system entirely.

Who can write a PT-141 prescription

Bremelanotide is not a controlled substance. That means any licensed prescriber acting within their scope of practice can, in principle, write for it — physicians (MD or DO), nurse practitioners, and physician assistants, subject to state law and collaborative-practice rules. There is no DEA scheduling hurdle the way there is for, say, testosterone.

In practice, prescribing tends to split by specialty and by which product is involved:

• Vyleesi is most often prescribed by clinicians who treat sexual desire disorders in women — OB-GYNs, women’s-health nurse practitioners, and sexual-medicine specialists — because the approved indication is HSDD in premenopausal women.
• Compounded bremelanotide is more commonly prescribed through telehealth sexual-wellness and men’s-health platforms, and by aesthetic, longevity, or hormone-optimization clinics that already work with compounding pharmacies.

A lot of general primary-care physicians will not prescribe PT-141 at all. It is unfamiliar to many, it sits in the off-label or compounded space for most patients, and the cardiovascular caution (below) makes some clinicians reluctant to take it on. That isn’t a sign the drug is unobtainable — it’s a sign that finding a prescriber often means going to someone who treats this category routinely. The generic landscape of which clinicians prescribe wellness peptides is covered on how to get peptides prescribed.

The clinical gate: why the evaluation isn’t a formality

This is the part that distinguishes a PT-141 prescription from many other wellness-peptide scripts, and it’s the single most important thing to understand.

Bremelanotide transiently raises blood pressure and slightly lowers heart rate after each dose. In clinical studies the rise was small — on the order of a few mmHg, peaking a couple of hours after dosing and usually returning to baseline within about half a day. But the approved labeling draws a hard line around it:

• It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
• It is not recommended for people at high risk for cardiovascular disease.
• Prescribers are told to consider cardiovascular risk before starting and periodically during treatment, and to make sure blood pressure is well controlled.

That turns the intake evaluation into a genuine safety gate rather than a box-ticking exercise. A responsible prescriber will ask about your blood pressure, heart history, and cardiovascular risk factors — and for an injectable that briefly nudges blood pressure upward, those questions are the point. A “prescription” issued without any of them isn’t a thinner version of the same service; it has skipped the one screen the labeling specifically requires.

There are a few other things a thorough evaluation covers:

• Pregnancy. Bremelanotide carries a pregnancy caution based on animal data, so the possibility of pregnancy is screened and effective contraception is discussed where relevant.
• Skin changes. A small share of users develop focal hyperpigmentation — darkened patches of skin, gums, or other areas — with risk higher in people with darker skin and with frequent dosing. A good provider mentions this up front rather than after the fact.
• Nausea. It’s the most common side effect by a wide margin, and setting that expectation is part of an honest consult.

The depth of PT-141’s adverse-effect profile lives on PT-141 side effects; the point here is simply that these are the things a real prescriber raises before writing the script.

How telehealth prescribing works for PT-141

Because bremelanotide isn’t a controlled substance, the federal rules that force an in-person visit before prescribing controlled drugs do not apply to it. That’s why so much PT-141 prescribing happens through telehealth.

But “no controlled-substance rule” is not the same as “no rules.” A telehealth provider still has to:

• Hold a valid license in your state (or use an appropriately licensed clinician for your location).
• Conduct a good-faith clinical evaluation that meets the medical standard of care — the same standard an in-person visit would.
• Document the evaluation and the basis for the prescription.

Through 2025 and into 2026, state medical and pharmacy boards have continued to scrutinize quiz-only, fully asynchronous prescribing, where a script is generated from a web form with no meaningful clinician assessment. That model is exactly the kind of corner-cutting that matters most for PT-141, because the cardiovascular screen is hard to do well from a checkbox. The practical tell of a legitimate telehealth provider is that they want a blood-pressure reading — they’ll ask for a recent number, have you use a home cuff, or otherwise confirm your blood pressure is controlled before prescribing. A platform that never raises the subject is the one to be wary of.

What the prescribing process looks like, step by step

For most people the path runs in the same order regardless of which product you end up with:

1. Intake and history. You complete a medical history and describe your goals. A real intake asks about blood pressure, heart disease, cardiovascular risk factors, medications, and (where relevant) pregnancy status.
2. Clinical evaluation. A licensed provider reviews your history — in person or by video/telehealth — screens for the contraindications above, and decides whether PT-141 is appropriate for you at all. This is where an unsuitable candidate should be turned away.
3. Product and route decision. The prescriber chooses between the approved product and a compounded preparation. For a patient outside the Vyleesi indication, that often means a compounded version, which is legally justified by a patient-specific factor such as a different route of administration than the approved injector. (The mechanics of that decision, and why it keeps the compound from being treated as a copy of Vyleesi, are detailed on the access pages.)
4. Pharmacy fill. A named pharmacy fills the prescription — a standard pharmacy for Vyleesi, or a licensed 503A compounding pharmacy for compounded bremelanotide.
5. Follow-up and monitoring. Because the labeling calls for periodic cardiovascular reassessment, a legitimate provider checks in rather than simply shipping refills indefinitely.

Notice what’s deliberately absent here: specific doses, injection amounts, and titration schedules. Those are clinical decisions a prescriber makes for an individual patient — not numbers to copy off a website — and this page won’t supply them.

State rules and the things that vary

Three things vary from state to state and pharmacy to pharmacy, and they explain why one person’s experience differs from another’s:

• Telehealth licensure. Your prescriber must be licensed for your state. National platforms handle this by routing you to an appropriately licensed clinician; smaller operations may simply not serve your state.
• Good-faith-exam standards. States differ in how strictly they define an acceptable telehealth evaluation, and enforcement has been tightening. The direction of travel is toward requiring a real assessment, not a form.
• Pharmacy willingness. Even with a valid prescription, individual compounding pharmacies decide which preparations they’ll make. Availability of a particular compounded form can therefore differ by region.

For anything legal or regulatory, treat the specifics as current to this page’s update date and subject to change — the compounding landscape in particular is still in motion, not finalized.

The 2026 regulatory backdrop, in brief

Two different stories sit behind a PT-141 prescription, and they’re moving at different speeds.

Vyleesi is stable. It’s an FDA-approved drug. Its prescription pathway doesn’t depend on the broader churn around which peptides can be compounded — it’s a normal brand prescription for an approved indication, dispensed through normal channels.

The compounded route is more conditional. Compounded bremelanotide is lawful when a 503A pharmacy fills a prescriber’s order that documents a patient-specific need. The key concept is that a compounded drug generally can’t be “essentially a copy” of an available approved product — so a meaningful, patient-specific change, such as a different route of administration (for example a non-injectable form) than Vyleesi’s autoinjector, is what supports compounding it. That framework, and how it interacts with the FDA’s 2026 enforcement posture on compounding, is the subject of compounded peptides: 503A vs 503B and the broader are peptides legal in the US? overview.

The takeaway for someone seeking a prescription: the approved path is settled, the compounded path is legitimate but governed by that patient-specific rule, and both still begin with the clinical evaluation this page has centered.

Red flags: when a “prescription” isn’t a real one

The single most useful filter is whether anyone actually evaluated you. Walk away if you see:

• No real evaluation — a script generated from a quiz with no clinician assessment.
• No questions about your blood pressure or heart health. For this specific drug, that omission is disqualifying.
• A prescription in minutes with no history, no follow-up plan, and no named pharmacy.
• Pressure to buy in bulk or to “stock up,” which is a sales tactic, not medicine.
• “Research use only” vials presented as if they were a prescription — they aren’t a patient route.

A legitimate provider does the opposite: evaluates you, screens for the cardiovascular contraindications, explains the side effects honestly, names the dispensing pharmacy, and follows up. If you’re vetting a clinic more broadly, how to choose a peptide clinic walks through the checks in detail.

Getting a PT-141 prescription, in other words, is less about finding a prescriber and more about finding one who treats the evaluation as the real work — because for bremelanotide, it is.